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Bernardi).The permeability transition pore (PTP) is an inner mitochondrial membrane channel that has been
thoroughly characterized functionally, yet remains an elusive molecular entity. The best character-
ized PTP-regulatory component, cyclophilin (CyP) D, is a matrix protein that favors pore opening.
CyP inhibitors, CyP-D null animals, and in situ PTP readouts have established the role of PTP as
an effector mechanism of cell death, and the growing deﬁnition of PTP signalling mechanisms. This
review brieﬂy covers the functional features of the PTP and the role played by its dysregulation in
disease pathogenesis. Recent progress on PTP modulation by kinase/phosphatase signal transduc-
tion is discussed, with speciﬁc emphasis on hexokinase and on the Akt-ERK-GSK3 axis, which might
modulate the PTP through CyP-D phosphorylation.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. General features of the permeability transition pore
The permeability transition pore (PTP) is a voltage- and Ca2+-
dependent, cyclosporin A (CsA)-sensitive, high conductance chan-
nel, whose opening leads to permeabilization of the inner mito-
chondrial membrane (IMM) to solutes with molecular masses
up to 1500 Da. A prolonged PTP opening has major consequences
on energy metabolism and cell viability. Mitochondria depolarize
due to equilibration of the proton gradient and the initial uncou-
pling is followed by release of matrix pyridine nucleotides result-
ing in respiratory inhibition and generation of reactive oxygenchemical Societies. Published by E
ucleotide translocator; CsA,
lar signal regulated kinase;
en synthase kinase 3; HK,
er mitochondrial membrane;
anion; PiC, phosphate carrier;
PKG, protein kinase G; PP2A,
2B; PP2Cm, mitochondrial
PTP, permeability transition
active oxygen species; RTKs,
sine phosphatase 1; TRAP-1,
; VDAC, voltage-dependent
omedical Sciences, University
Italy. Fax: +39 049 827 6361.
), bernardi@bio.unipd.it (P.species (ROS) via the direct transfer of electrons to molecular
oxygen. Oxidative phosphorylation and ATP synthesis cease, and
the F0F1 ATP synthase starts working in reverse, hydrolyzing
ATP generated by glycolysis or by residual functional mitochon-
dria. As a result, a bioenergetic failure rapidly occurs [1]. More-
over, ions and solutes with molecular mass below the pore size
equilibrate across the IMM, inducing disruption of metabolic gra-
dients and release of the Ca2+ stored in the matrix. The colloidal
osmotic pressure exerted by the high protein concentration in
the matrix causes its swelling. Inner membrane cristae unfold
and eventually may disrupt the outer membrane, leading to re-
lease of intermembrane proteins, including pro-apoptotic factors
[2]. Thus, PTP opening prompts the demise of the cell, either
through apoptosis (if enough ATP is present to fuel caspase activ-
ity), or through necrosis (that follows loss of Ca2+ homeostasis
and mitochondrial dysfunction). The mode of cell demise could
be necrotic when the permeability transition (PT) occurs in a frac-
tion of mitochondria sufﬁcient to cause ATP depletion. A more
limited number of permeabilized mitochondria would lead to re-
lease of proapoptotic factors, and ATP production by the residual
healthy mitochondria would be enough to support apoptosis exe-
cution. In a cell, a subpopulation of mitochondria may have a
lower threshold for opening (e.g. those spatially closer to the trig-
gering signal) and therefore open the PTP ﬁrst. Ca2+ or other dif-
fusible signals such as superoxide sparks [3] will then be sensed
by other mitochondria, spreading PTP opening to the surroundinglsevier B.V. All rights reserved.
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chondrial depolarization could have functional implications. For
instance, mitochondria isolated from synaptosomes have a lower
threshold for PTP opening than mitochondria from other regions
of the neuron [4]. It is possible to envisage a scenario in which
synaptic damage does not diffuse to the neuron soma. It is also
possible that PTP is involved in the autophagic disposal of dam-
aged or aging mitochondria, which would become more suscepti-
ble to pore opening [1].
Given the importance of the PTP for cell biology, it comes as no
surprise that its open–closed transitions are strictly regulated by a
number of effectors, including a wide variety of cell death regula-
tors. The undecapeptide CsA desensitizes the pore, i.e. increases its
opening threshold by binding the mitochondrial chaperone cyclo-
philin D (CyP-D) [5]. Experiments performed on isolated mitochon-
dria have shown that an increase in the matrix Ca2+ content is a key
permissive factor for most PTP inducers; Ca2+ effect can be compet-
itively inhibited by other Me2+ ions, such as Mg2+, Sr2+ and Mn2+
[6]. However, we have recently found that CyP-D masks an inhib-
itory site for phosphate anion (Pi), which is the actual PTP desensi-
tizing agent [7]. In fact, when Pi was replaced by other anions, the
sensitivity of the PTP to Ca2+ remained identical in naïve and CsA-
treated wild type mitochondria, as well as in CyP-D null mitochon-
dria. We postulate that CyP-D favors the PTP open conformation by
making the Pi site on the pore not available. When CyP-D is absent
or bound to CsA, Pi binding to the PTP lowers its open probability,
given a sufﬁcient free Pi concentration. As a consequence, PTP
induction in cells would be modulated by local changes in Pi con-
centration. This could be particularly relevant for non-excitable
cells; conversely, in cardiomyocytes or neurons oxidant stress
mechanisms appear to be dominant factors responsible for PTP
opening [8]. Accordingly, pro-oxidants molecules (like tert-butyl-
hydroperoxide, diamide, phenylarsine oxide) are recognized pore
inducers, whereas proteins involved in antioxidant defences (like
catalase, superoxide dismutase and glutathione) act as pore desen-
sitizers [6]. Proton concentration also regulates the PTP. The opti-
mum for pore opening is observed at matrix pH 7.4, whereas the
opening probability sharply decreases either by lowering or by
increasing matrix pH [9]. The PTP is voltage-dependent, and a high
(inside negative) membrane potential stabilizes it in the closed
conformation. We have postulated the existence of a sensor
that translates the changes of either the transmembrane voltage
or the surface potential into changes of the PTP open probability
[10].2. The channel
These observations match data obtained studying the PTP by
electrophysiological means in mitoplasts [11]. The channel was
found to locate in the IMM or at residual contact sites between
mitochondrial membranes, and displays a maximal conductance
in the 0.9–1.3 nS range [11,12]. Conductance substates can be re-
corded. A characteristic half-conductance or hemichannel is com-
patible either with a dimeric structure, or with a channel capable
of entering a conformation with half the maximal conductance.
Rapid conversions among conductance substates of the channel
(ﬂickerings) could allow passage of protons or Ca2+ without equil-
ibration of small molecular weight metabolites. These transient
PTP openings would not be associated with irreversible mito-
chondrial changes, but with physiological roles of the PTP, such
as regulation of protein import, of matrix volume and pH, cristae
remodeling, redox equilibrium, and Ca2+ release [1,10]. Electro-
physiological properties of the hemichannel also include Ca2+-
dependence, with high (P100 lM) Ca2+ needed to observe sus-
tained activity, and anion-selectivity, with a ratio of permeabilitycoefﬁcients PCl/PK  7–18. However, for short periods and in rare
cases the channel can display cation-selective conductances, and
this selectivity was also observed in different experimental set-
tings [12]. Also similarly to established PTP features, ATP or
Mg2+ at acid pH and reducing agents are able to inhibit the chan-
nel. The pattern of voltage sensitivity is complex. The hemichan-
nel is open in the absence of any transmembrane voltage, but
often shows a tendency to close at positive or negative
(640 mV) voltages. Nonetheless, some channels promptly close
at low (<40 mV) voltages, whereas others require prolonged
application of higher potentials. These changes cannot depend
on stochastic variations, as repeated applications on the same
patch of voltage protocols always induce the same channel re-
sponse [11,13,14]. It was therefore postulated that this variability
in voltage-dependence is caused either by interactions with regu-
latory proteins or by post-translational modiﬁcations, possibly
phosphorylation, of the voltage sensor. Accordingly, several lines
of evidence point towards a role of phosphorylations in PTP mod-
ulation (see below).
Other channels could also affect PTP activity. Following its
electrochemical gradient, K+ enters the matrix through IMM
channels, whose inhibition results in hyperpolarization, which
in turn enhances ROS production by reducing respiratory chain
components. As widely reported, ROS oxidize thiols and thus
open the PTP. PTP opening downstream to transient mitochon-
drial hyperpolarization has been reported in several studies.
Alternatively or in addition, ROS could open the pore following
activation of kinase signalling pathway. According to this view,
in mitoplasts hypoxia opens the mitochondrial BK-channel and
inhibits the PTP [15], and inhibitors of this BK-channel or of a
mitoKATP channel sensitize the pore, measured as CsA-sensitive
mitochondrial swelling [15,16]. Recently, a voltage-dependent,
Shaker-like K+ channel, termed KV1.3, has been characterized in
the IMM. KV1.3 is endowed with a rapid opening following depo-
larization, and its inhibition with selective toxins prompts ROS
production and a CsA-sensitive mitochondrial depolarization,
indicating PTP opening. The action of the toxins can be mimicked
by a speciﬁc residue on the pro-apoptotic protein Bax, which can
similarly block the channel triggering cytochrome c release and
apoptosis [17]. This observation is particularly important, as it of-
fers a possible functional link between apoptotic pathways gov-
erned by Bcl-2 family proteins and the PTP. However, the
functional connection between K+ channel regulation and PTP
opening is controversial, and experimental results probably
dependent on the context. A viral protein, the HTLV-1 p13, trig-
gers an inward mitochondrial K+ current. The ensuing depolariza-
tion induced by p13 was proposed to increase production of ROS
by enhancing respiratory chain activity, eventually lowering the
threshold for PTP opening [18].3. The core of the pore: molecular structure of the PTP
The precise mechanisms of PTP regulation are only partially
understood, as the molecular structure of the pore remains an un-
solved riddle. The present consensus model postulates that the
channel is originated by a supramolecular complex. Several layers
of complexity render dissection of single components a difﬁcult
task. Assemblage of PTP components might be a rare event, to
avoid unwanted mitochondrial depolarization and damage. It is
also possible that, in particular cell types or following speciﬁc trig-
gering conditions, different protein multimers assemble to form
the PTP, possibly resulting in diverse sensitivities to modulators
or in changes of conductance properties [8]. A subset of proteins
was proposed to constitute core components of the channel, but
rigorous genetic testing in the last few years has excluded this pos-
A. Rasola et al. / FEBS Letters 584 (2010) 1989–1996 1991sibility for most of them. These candidate components included the
outer mitochondrial membrane (OMM) porin, aka voltage-depen-
dent anion channel (VDAC); the matrix chaperone CyP-D; the ade-
nine nucleotide translocator (ANT) in the IMM; and more recently
the mitochondrial phosphate carrier (PiC).
Evidence linking VDAC to the PTP included the observations
that its activity is modulated by many factors that also affect the
PTP, such as NADH, Ca2+ and glutamate. Disruption of the binding
between hexokinase (HK) and VDAC onto mitochondria was re-
ported to prompt PTP opening and cell death [19]. Accordingly,
we have observed that HK displacement from mitochondria in-
duces PTP opening and apoptosis, but this occurs even in the ab-
sence of any binding between HK and each of the three VDAC
isoforms, whereas disassembly of the HK/VDAC complex could be
observed in conditions that inhibit pore opening, i.e. following cell
treatment with the CsA analogue Debio 025 [20]. In addition, the
PTP of mitochondria prepared from VDAC1/, VDAC3/ and
VDAC1/3/ mice, or from ﬁbroblasts lacking all three VDAC iso-
forms, was indistinguishable from the PTP of strain-matched
wild-type mitochondria [21]. Altogether this set of results clearly
indicates that the VDAC isoforms are not component of the PTP
[22]. Nonetheless, it was recently shown that VDAC can transduce
a PTP-sensitizing signal elicited by dephosphorylation of the pro-
apoptotic Bcl-2 protein Bad [23].
The PTP is sensitized by the matrix peptidyl-prolyl cis–trans
isomerase CyP-D. However, the pore is still present in mitochon-
dria and cells obtained from mice where the gene encoding CyP-
D was knocked-out. CyP-D ablation increases the Ca2+ load re-
quired to open the PTP, unmasking inhibition by Pi (see above),
and abolishes sensitivity to the CyP-D ligand CsA, conclusively
demonstrating that CyP-D is an important regulator of the PTP,
but not a component of the channel (reviewed in [10]).
It is plausible that the PTP is composed by proteins spanning the
IMM, such as exchangers or ion channels [22]. The PTP is strikingly
modulated by ligands of one such protein, the ANT, which ex-
changes ATP with ADP through the IMM. However, the attractive
hypothesis that one or more ANT isoforms are constituents of the
pore is not compatible with the ﬁnding that mitochondria obtained
from ANT1/2/ double knock-out mice undergo a Ca2+- and oxi-
dant-dependent, CsA-sensitive PT. ANT could be a peripheral PTP
regulator, similarly to CyP-D. In fact, ANT null mitochondria re-
quire a larger Ca2+ load than their wild-type counterparts to open
the PTP, which becomes insensitive to ANT ligands [24]. Accord-
ingly, we have found that ANT interacts with CyP-D, and that pore
induction triggered by detachment of HK II from mitochondria not
only disrupts this interaction, but is inhibited by the ANT ligand
bongkrekate [20]. It was claimed that a more recently discovered
ANT isoform could be involved in pore formation. However, this
is restricted to speciﬁc cell types, whereas the PTP is ubiquitously
found; in addition, this ANT isoform should be able to promote a
CsA-sensitive PT and yet not respond to classical ANT ligands [25].
Recently another IMM transporter, the mitochondrial PiC, has
been shown to interact with CyP-D. This interaction is increased
in conditions that induce the PTP and reduced by pore desensitiz-
ers. Moreover, inhibition of Pi transport desensitizes the PTP in iso-
lated mitochondria [26]. A rigorous genetic analysis is needed to
establish whether the PiC is a component of the channel, or a fur-
ther PTP regulator. Interestingly, as Pi is required for PTP inhibition
[7], regulation of PiC by its substrate could affect pore opening
[25].
Finally, the disappointing deﬁciency of information on pore
components is further highlighted by the observation that the elec-
trophysiological properties of the hemichannel whose dimers are
thought to form the PTP are different from those of all the charac-
terized mitochondrial channels (including VDAC, ANT and PiC), butmatch those of plasma membrane ‘‘maxi-Cl channels”, whose
molecular identity is however undeﬁned [11].4. PTP and pathogenesis: more and more pore diseases
PTP-dependent mitochondrial dysfunction and PTP deregula-
tion are involved in a variety of diseases characterized by altera-
tions in the molecular mechanisms that control cell death. In
pioneering work of the early 1990s, the protective effect of CsA
was used to establish a role of the PTP in hepatocytes subjected
to oxidative stress or anoxia, and in cardiomyocytes and isolated
hearts exposed to ischemia-reperfusion. Later on, the PTP was
implicated in many other diseases, including various forms of
brain damage, amyotrophic lateral sclerosis, muscular dystrophy
caused by collagen VI deﬁciency, acetaminophen hepatotoxicity
and fulminant, death receptor-induced hepatitis (reviewed in
[10,27]). In recent years, other disorders have been related to
the PTP. In a mouse model of the human lysosomal storage dis-
ease GM1-gangliosidosis, GM1-ganglioside induces mitochondrial
Ca2+ overload, opening of the pore and apoptotic cell death [28].
Dysregulation of mitochondrial Ca2+ homeostasis and the follow-
ing increased sensitivity of the PTP was reported in neuron mod-
els of Huntington disease [29,30]. Snake neurotoxins with a
phospholipase activity penetrate spinal cord motor neurons and
cerebellar granule neurons, bind to mitochondria and facilitate
PTP opening [31].
CyP-D knockout mice were used to study several pathologies,
particularly of the central nervous system. PTP opening induces
brain injury following hypoxic ischemia in the adult animal,
whereas in neonatal mice CyP-D protects from ischemic conditions
and the pore displays a higher induction threshold [32]. In an
amyotrophic lateral sclerosis mouse model, the genetic deletion
of CyP-D delays onset of the disease and extends survival [33].
Experimental autoimmune encephalomyelitis mice are a model
of multiple sclerosis, as they develop symptoms similar to the hu-
man disease when treated with a myelin peptide. Disease progres-
sion is dramatically reduced by CyP-D ablation, with a striking
inhibition of axonal damage [34]. The amyloid beta (Ab) peptide,
whose massive deposition in the brain is a hallmark of Alzheimer’s
disease, has been reported to interact with CyP-D. In an Alzhei-
mer’s disease mouse model, the absence of CyP-D protects cortical
neurons from PT and cell death induced by Ab and Ca2+, improves
learning and memory and synaptic function [35] also in aged ani-
mals [36]. It should also be mentioned that CyP-D knockout mice
have an interesting psychological phenotype with increased anxi-
ety, facilitation of avoidance behavior; and that they develop
adult-onset obesity independent of food and water intake [37]. Fi-
nally, CyP-D ablation protects from cell death in ischemic renal in-
jury [38].
PTP opening has been examined extensively in cardiac ische-
mia/reperfusion injury. Ischemia is deﬁned as an imbalance be-
tween oxygen supply and demand. In these conditions,
mitochondria halt ATP synthesis, cells accumulate glycolytic lac-
tate, and in the attempt to restore intracellular pH activate the
plasma membrane Na+/H+ exchanger, whereas the Na+/K+-ATPase
activity is suppressed. The ensuing increase in intracellular Na+
stimulates the Na+/Ca2+ exchanger, and together with the block
of reticular Ca2+-ATPases this increases intracellular Ca2+. More-
over, the ischemic cell can maintain an oxygen level sufﬁcient to
generate ROS, and a burst of ROS, with further progression of
Ca2+ overload caused by the Na+–Ca2+ exchanger, is generated in
the ﬁrst minutes of reperfusion. Altogether, Ca2+ overload and even
more importantly oxidative stress [39] provide ideal circumstances
for opening of the PTP, leading to cytochrome c release and cell
death [40]. A protective effect of PTP desensitization through CsA
1992 A. Rasola et al. / FEBS Letters 584 (2010) 1989–1996has been demonstrated in different models of ischemia followed by
reperfusion. At present, inhibition of pore opening by non-immu-
nosuppressive analogs of CsA or antioxidants is the most promising
therapeutic approach [22,25,41].
Recent data suggest that PTP dysregulation is involved in
tumorigenesis. Neoplastic cells are more resistant than non-trans-
formed cells to PTP-induced mitochondrial damage, and this is in-
volved in resistance to chemotherapeutics and in the ability
acquired by tumor cells to escape apoptosis induced by a variety
of stressful conditions, such as hypoxia or detachment from the
extracellular matrix [10]. PTP opening was recently found to trig-
ger death of keratinocytes exposed to UV light, whereas CsA-in-
duced PTP desensitization induced tumor formation [42]. In the
rodent model of hepatocarcinogenesis caused by 2-acetylaminoﬂu-
orene, desensitization of the PTP is an early adaptive response of
hepatocytes that acts as a tumor-promoting event [43]. Also other
conditions that predispose to liver cancer (alcoholic liver disease,
chronic hepatitis C and cholestasis) were proposed to involve PTP
deregulation [10]. In this framework, we have recently found that
transformation of a prostate cell model induces PTP desensitization
and resistance to cell death [44].5. Switching a pore: signal transduction to the PTP
In the past, extensive analyses have dissected the factors that
regulate the PTP in situ [6]. Nonetheless, extreme caution must
be exerted when these data are extrapolated to PTP modulation
in the living cell. The continuous crosstalk between mitochondria
and other cell compartments suggests that several proteins can
play regulatory roles on the pore, connecting signaling cascades
known to control the apoptotic process with the PTP, as this is a
key switch in the cell commitment to death.
An example of these regulatory components is hexokinase (HK).
HK initiates all major pathways of intracellular glucose utilization,
and type II hexokinase (HK II) is highly expressed in most cancer
cells, where it mainly localizes on the OMM (Fig. 1A).
Mitochondrial HK II is extremely important in neoplastic trans-
formation. In highly glycolytic, aggressive tumors, it fosters cell
growth in the hypoxic conditions of primary tumor mass accrual.
This would contribute to the Warburg effect, i.e. to the uncoupling
between glycolysis enhancement and oxygen availability, support-
ing cell proliferation when the neoplastic mass outgrows the sur-
rounding blood vessels. Accordingly, in hepatocellular carcinoma
cells hypoxia stimulates growth via HK II induction, whereas HK
II inhibition induces apoptosis [45], and release of HK II from mito-
chondria prompts apoptosis in glioma cells [46]. Detachment of HK
II from mitochondria by a selective peptide induces PTP opening
and cell death in tumor cell models and in cardiomyocytes
[20,47]. In experiments with CsA and CsA derivatives, and with
cells and mitochondria derived from CyP-D knock-out mice, we
have shown that CyP-D enhances PTP opening and the ensuing
apoptosis triggered by detachment of HK II from mitochondria
[20]. These observations suggest that mitochondrial HK II delivers
a survival signal that stabilizes the PTP in the closed conformation,
whereas HK II detachment from mitochondria would propagate a
conformational change to molecules of the inner mitochondrial
membrane, eventually leading to pore opening (Fig. 1B). Moreover,
in this model the knockout of CyP-D inhibits apoptosis, at variance
from what has been reported in other experimental settings
[48,49]. However, it remains unclear what mediates the interaction
between HK II, which is located on the mitochondrial surface, and
PTP regulators or components in the inner mitochondrial
compartments.
Signal transduction pathways converge on mitochondrial HK II
(Fig. 1A and B). This is of pivotal importance in cancer, because tu-mor cells are endowed with hyper-activation of anabolic path-
ways. Thus, by integrating information from growth factor
signalling, mitochondrial HK II could act as a potent anti-apoptotic
‘‘porekeeper” to suppress cell death either in conditions of ade-
quate nutrition or when kinase pathways are aberrantly boosted
by malignant transformation. The survival kinase Akt, which is
activated by growth factors and in most tumor cells, promotes
HK II binding to mitochondria. Indeed, Akt phosphorylates both
HK II itself or glycogen synthase kinase 3b (GSK3b). Akt-dependent
phosphorylation of mitochondrial HK II inhibits Ca2+-induced cyto-
chrome c release [50], and association of HK II to the OMM is fa-
voured when GSK3b is inactivated by Akt phosphorylation
[51,52]. Accordingly, activation of GSK3b was shown to induce re-
lease of HK II, enhancing susceptibility to cell death [51,52]. This
was proposed to require GSK3b phosphorylation of VDAC, which
would displace Bcl-2 from its interaction with VDAC, favoring the
binding between VDAC and the pro-apoptotic Bax/Bak proteins in
conditions of growth factor deprivation [51,52]. This would result
in increased sensitivity of mitochondria to PTP induction. However,
mitochondrial displacement of HK II induced cell death also after
insulin-dependent Akt activation or in cells lacking VDAC1 and 3
(and without any detectable binding between HK II and residual
VDAC2) [20], and even in the absence of Bax and Bak [53] (also dis-
cussed in [8]).
PTP regulation by kinase signalling has been widely investi-
gated, particularly in cardiac models. A group of kinases, termed
RISK (reperfusion injury salvage kinase), confers cardioprotection
when activated during post-ischemic myocardial reperfusion or
ischemic pre- and post-conditioning [54]. Several agents, including
growth factors and hormones, reduce myocardial infarct size by
activation of the RISK pathway (Fig. 2). RISKs include the survival
kinases Akt and Erk1/2, protein kinase Ce (PKCe), protein kinase
G (PKG) and p70s6K, and protect from cell death by phosphoryla-
tion of Bcl-2 family proteins and inhibition of the mitochondrial
PTP, with a possible interplay between these events [54].
A substrate of the RISK pathway is GSK3bwhich, unlike most ki-
nases, is constitutively active in unstimulated cells, exerting a tonic
inhibitory effect on its downstream targets [55]. GSK3b is inacti-
vated by serine phosphorylation induced by a variety of signalling
pathways, whereas autophosphorylation at a speciﬁc tyrosine in-
creases its overall catalytic efﬁciency. Deregulation of this GSK3b
ﬁne tuning has been associated with a variety of diseases, such
as neurodegenerative diseases, cancer and ischemia/reperfusion
injury, which involve disturbances in apoptosis regulation [55].
In cardiomyocytes, receptor tyrosine kinase or G protein-coupled
receptor activation, or ROS production induced by reoxygenation
after prolonged hypoxia lead to activation of diverse RISK compo-
nents, and ultimately converge on PTP desensitization downstream
of inactivating GSK3b phosphorylation [56]. Accordingly, expres-
sion of a constitutively active GSK-3b failed to protect myocytes
against oxidative stress, whereas transfection with a kinase-dead
enzyme was protective [47,57,58]. Moreover, infarct size in mice
was reduced by CsA and by a GSK3b inhibitor, whereas in mice
expressing a constitutive active GSK3b only CsA was effective
[59]. As in mitochondria from wild-type animals the PTP inhibitory
effect of CsA and of the GSK3b inhibitor were additive, it was pro-
posed that GSK3b facilitates pore opening independently of CyP-D
[59].
This PTP regulation is operated by changing the ROS and/or Ca2+
threshold of PTP opening, and should be elicited by a mitochon-
drial pool of GSK3b acting as an integration point to funnel a mul-
tiplicity of survival pathways to target(s) at or in close proximity to
the PTP (Fig. 2). Nonetheless, further layers of complexity are in-
volved in this picture. For instance, a knock-in mouse with a con-
stitutive active GSK3 (i.e. that cannot be phosphorylated on
regulatory serine) displayed heart protection when pre- or post-
Fig. 1. PTP regulation by mitochondrial hexokinase (HK). (A) Akt activation by receptor tyrosine kinases (RTKs) or during neoplastic transformation keeps HK bound to the
mitochondrial surface, both through a direct HK phosphorylation and through an inactivating serine phosphorylation of GSK3b. Inactive GSK3b cannot phosphorylate VDAC,
favoring its binding to HK and to anti-apoptotic Bcl-2 family proteins, and displacing the binding of pro-apoptotic Bax/Bak. However, VDAC is dispensable for HK interaction
with mitochondria, suggesting that (an) unknown partner(s) is/are involved in this process. HK utilizes the ATP synthesized by mitochondria to start glucose metabolism, and
stabilizes the PTP in a closed state. (B) Either Akt inactivation or treatment with a HK peptide induce HK detachment from the outer mitochondrial membrane, possibly
leading to conformational changes of ANT and CyP-D and eventually to PTP opening and cell death. GSK3b is activated by Akt inhibition. The ensuing VDAC phosphorylation
leads to Bcl-2/XL displacement and favors Bax/Bak activation, but PTP opening induced by HK detachment from mitochondria does not require VDAC.
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to limit infarct size in these animals [60]. Hence, these knock-in
mice might have developed alternative ways to negatively regulate
GSK3b (discussed in [47]). In accord with this possibility, it must be
stressed that GSK3b has further regulatory mechanisms, including
phosphorylation at additional Ser residues, complex formation
with scaffold proteins, priming of substrates and of the enzyme it-
self and intracellular translocation (reviewed in [41,47,55]). More-
over, GSK3b could indirectly regulate the PTP in several ways.
These include the already discussed modulation of HK II binding
to mitochondria, regulation of the interaction between ANT and
CyP-D, mitochondrial translocation of pro-apoptotic Bcl-2 family
members, degradation of anti-apoptotic Bcl-2-like proteins
[41,47]. GSK3b inhibition also reduces infarct size via the opening
of ATP-dependent K+ channels and the ensuing PTP closure [61],
and phosphorylation of mitochondrial serine/threonine protein
phosphatases (e.g. the subunit B of protein phosphatase 2A that
possesses a consensus site for GSK3b) could directly affect the pore.
Indeed, a mitochondrial matrix-targeted protein phosphatase 2C
family member (PP2Cm) was shown to inhibit PTP opening and
to be essential for cell survival [62], whereas PTP-mediated apop-
tosis was shown to be inducible by the protein phosphatases 2B[63] and SH2-containing tyrosine phosphatase 1 [64] in different
cell models.
It is possible that other kinase/phosphatase signaling pathways
can converge on the PTP through GSK3b regulation, or alternatively
bypass it to directly impinge on the pore. PKCe plays a critical role
in cardioprotective signalling pathways, targeting mitochondrial
ATP-sensitive K+ channels, respiratory chain components, ROS pro-
duction and both ANT and VDAC. PKCe can inhibit PTP opening in a
phosphorylation-dependent reaction and also in isolated mito-
chondria, conferring protection from reperfusion-induced cell
death [65,66]. The master survival kinase Akt protects the ischemic
heart through inhibition of the PTP [67], and growth factors pro-
vided before ischemia reduce infarct size and increase the fraction
of activated Akt in mitochondria, where it complexes with ANT
upon reperfusion [68]. As in the case of GSK3b, Akt could also indi-
rectly modulate pore opening through the targeting of Bcl-2 family
proteins, either affecting their subcellular localization or their deg-
radation or regulating them at the transcriptional level [69]. In
hepatoma cells Akt inactivation by oxidative stress induces mito-
chondrial injury associated with opening of the PTP but indepen-
dently of both GSK3b and Bcl-2 family proteins [70]. In
pheochromocytoma cells, GSK3b causes mitochondrial pore open-
Fig. 2. Kinase signalling to the PTP. Several kinase pathways converge on PTP regulation. A common target, at least during post-ischemic reperfusion, is GSK3b, which is
inactivated by a group of survival kinases termed RISK (reperfusion injury salvage kinases). A small pool of GSK3b is in the mitochondrial matrix, where it favors PTP opening,
possibly through CyP-D phosphorylation. In tumors, mitochondrial GSK3b is inactivated by ERK-dependent phosphorylation, raising the threshold for pore opening and
therefore enhancing cell survival. GSK3b inactivation, and PKCe activity, could also contribute in keeping closed the PTP by opening mitochondrial KATP channels. CyP-D
regulation of the pore is also inﬂuenced by the chaperones Hsp90 and TRAP-1; TRAP-1 is activated by the Ser/Thr kinase PINK1. Finally, PTP opening is inhibited by the
phosphatase PP2Cm through unknown mechanisms. RTKs: receptor tyrosine kinases; GPCRs: G protein coupled receptors.
1994 A. Rasola et al. / FEBS Letters 584 (2010) 1989–1996ing and the subsequent cell death via upregulation of the stress ki-
nase c-Jun N-terminal kinase [71].
Several factors render extremely difﬁcult a better deﬁnition of
the effects of kinase/phosphatase signalling on the PTP. As it is al-
ways the case for (de)phosphorylation events, critical components
are the timing, duration and intensity of the signal, which are in
turn dependent on the cell type, the subcellular localization of scaf-
folding, adapter and regulatory proteins, on the assembly of multi-
meric complexes and even on speciﬁc non-proteinaceous
components (e.g. lipid species). In addition, the absence of recog-
nized mitochondrial import sequences in most known kinases
ask for laborious investigations to assess the direct interaction be-
tween these enzymes and molecules located in inner mitochon-
drial compartments. The limited knowledge of proteins that
regulate the pore, and the lack of information on PTP components,
make an arduous task the subtle dissection of the interplay be-
tween kinase pathway and the pore, and of its functional meaning.
In this framework, an important role can be played by molecular
chaperones (Fig. 2). A chaperone homologous to heat shock protein
90 (Hsp90), termed tumor necrosis factor receptor-associated pro-
tein-1 (TRAP-1), is localized in mitochondria of tumor cells and of
nervous tissue, but not in most normal tissues [72,73]. Both TRAP-
1 and the mitochondrial fraction of Hsp90 interact with CyP-D and
antagonize its function of PTP sensitization [72]. Short hairpin
RNA-mediated knockdown of TRAP-1 enhances a CsA-inhibitable
cell death, whereas TRAP-1 overexpression confers resistance to
pro-apoptotic drugs [72], suggesting that TRAP-1/Hsp90 are novel
mitochondrial survival factor acting as PTP inhibitors, and consti-
tute possible targets of mitochondria-directed chemotherapeutics
drugs [74]. Importantly, TRAP-1 was shown to be substrate of
the Ser/Thr kinase PTEN induced kinase 1 (PINK1) in the mitochon-
drial matrix, and this phosphorylation was required to prevent oxi-
dative-stress-induced apoptosis [73]. Overexpression of PINK1
blocked PTP-dependent cell death [75], whereas PINK1 deﬁciency
lowers the threshold of PTP opening by impairing intracellular
Ca2+ homeostasis and enhancing ROS production in neurons [76].Altogether, these results further indicate that phosphorylation
events can be crucial in the regulation of the PTP, and that molec-
ular chaperones as TRAP-1 might be a link between kinase path-
ways and the pore. Furthermore, this could have important
pathogenic implications, both in tumors, where TRAP-1 overex-
pression could substantially contribute to ‘‘lock” the PTP in front
of diverse insults, and in neurodegenerative diseases. In fact, it
was shown that the cell survival function of PINK1 requires its abil-
ity to phosphorylate TRAP-1, and that this activity gets lost in the
presence of PINK1 mutations causing an autosomal recessive form
of Parkinson disease [73,77].
We have recently shown that also CyP-D is phosphorylated on
serine/threonine residues in tumor cell models [44]. A stepwise
protease digestion assay indicated that a small portion of both
extracellular signal regulated kinase (ERK) and GSK3 was located
in the mitochondrial matrix in several neoplastic cell models, and
that both kinases directly interacted with CyP-D. Mitochondrial
ERK turned out to be constitutively active after v-Ki-Ras dependent
transformation or in diverse tumor models, conferring resistance
to death stimuli acting as PTP inducers. This protection could be
ablated by inhibiting ERK with the drug PD98059 or with a selec-
tive ERK activation inhibitor peptide. Notably, these treatments en-
hanced GSK-3-dependent phosphorylation of CyP-D and PTP
opening, and the effect on the pore was increased after CyP-D over-
expression and absent in CyP-D knock-out cells. Accordingly, a re-
combinant GSK3 could phosphorylate CyP-D in vitro, and an in
silico analysis identiﬁed possible GSK-3 target residues on CyP-D.
Conversely, ERK activation prompted the inhibitory phosphoryla-
tion of GSK3 and abolished CyP-D phosphorylation, and GSK-3
pharmacological inhibition protected from PTP opening.
Thus, in diverse tumor cell models resilience to undergo cell
death is caused by ERK activity, which could directly impinge upon
pore opening through the negative regulation of CyP-D phosphor-
ylation by inhibiting the mitochondrial pool of GSK3. Mitochon-
dria-speciﬁc ERK activation might provide a key advantage
during neoplastic transformation, by placing the death/survival
A. Rasola et al. / FEBS Letters 584 (2010) 1989–1996 1995mitochondrial rheostat in an anti-apoptotic mode. To make this
picture more complex, it must be highlighted that ERK is a GSK-3
priming kinase, requiring the activity of a second kinase for com-
plete GSK-3 inhibition; and that GSK-3 itself needs a priming ki-
nase to phosphorylate its targets. Moreover, these reactions must
be ﬁnely tuned by the action of phosphatases.
From the above, we postulate that a network of phosphoryla-
tion events might control PTP regulation by modulating the activ-
ity of molecular chaperones such as TRAP-1 or CyP-D.
Dysregulation of kinase signalling pathways is a hallmark of a
number of diseases, in primis cancer, and the mitochondrial pore
could constitute an important downstream effector in conferring
crucial pathogenic traits, such as alterations in cell death re-
sponses, and an attractive pharmacological target.
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